6.7.3. treatment decisions sequence available options. approved agents treatment mcrpc europe docetaxel, abiraterone/prednisolone (aap), enzalutamide, cabazitaxel, olaparib, niraparib/aap, talazoparib/enzalutamide, radium-223 lutetium (177lu) vipivotide tetraxetan. regarding crpc, darolutamide apalutamide approved nmcrpc. general, sequencing arpis like abiraterone enzalutamide recommended particularly time response adt first arpi short (â‰¤ six twelve months) high-risk features rapid progression present (see detailed discussion section 6.7.7) . use chemotherapy docetaxel subsequent cabazitaxel treatment sequence recommended applied early enough patient still fit chemotherapy. supported high-level evidence .